Are parkin patients particularly suited for deep-brain stimulation?

Authors

  • Ebba Lohmann MD,

    1. INSERM, U679, Paris, France
    2. Pierre and Marie Curie-Paris6 University, UMR S679, Pitié-Salpêtrière Hospital, Paris, France
    3. Federative Institute for Neuroscience Research (IFR70), Pitié-Salpêtrière Hospital, Paris, France
    Search for more papers by this author
  • Marie-Laure Welter MD,

    1. AP-HP, Pitié-Salpêtrière Hospital, Centre d'Investigation Clinique, Paris, France
    2. AP-HP, Pitié-Salpêtrière Hospital, Fédération des Maladies du Système Nerveux, Paris, France
    Search for more papers by this author
  • Valérie Fraix MD,

    1. Département de Neurologie, CHU Grenoble, Grenoble, France
    Search for more papers by this author
  • Paul Krack MD,

    1. Département de Neurologie, CHU Grenoble, Grenoble, France
    Search for more papers by this author
  • Suzanne Lesage MD,

    1. INSERM, U679, Paris, France
    2. Pierre and Marie Curie-Paris6 University, UMR S679, Pitié-Salpêtrière Hospital, Paris, France
    3. Federative Institute for Neuroscience Research (IFR70), Pitié-Salpêtrière Hospital, Paris, France
    Search for more papers by this author
  • Sophie Laine BS,

    1. INSERM, U679, Paris, France
    2. Pierre and Marie Curie-Paris6 University, UMR S679, Pitié-Salpêtrière Hospital, Paris, France
    3. Federative Institute for Neuroscience Research (IFR70), Pitié-Salpêtrière Hospital, Paris, France
    Search for more papers by this author
  • Marie-Laure Tanguy MD, PhD,

    1. 2AP-HP, Pitié-Salpêtrière Hospital, Service de Biostatistique, Paris, France
    Search for more papers by this author
  • Jean-Luc Houeto MD,

    1. Service de Neurologie, CHU Poitiers, France
    Search for more papers by this author
  • Valérie Mesnage MD,

    1. 2AP-HP, Pitié-Salpêtrière Hospital, Service de Biostatistique, Paris, France
    Search for more papers by this author
  • Pierre Pollak MD,

    1. Département de Neurologie, CHU Grenoble, Grenoble, France
    2. INSERM U318, Joseph Fourier University, Grenoble, France
    Search for more papers by this author
  • Alexandra Durr MD, PhD,

    1. INSERM, U679, Paris, France
    2. Pierre and Marie Curie-Paris6 University, UMR S679, Pitié-Salpêtrière Hospital, Paris, France
    3. Federative Institute for Neuroscience Research (IFR70), Pitié-Salpêtrière Hospital, Paris, France
    4. AP-HP, Pitié-Salpêtrière Hospital, Department of Genetics and Cytogenetics, Paris, France
    Search for more papers by this author
  • Yves Agid MD, PhD,

    1. INSERM, U679, Paris, France
    2. Pierre and Marie Curie-Paris6 University, UMR S679, Pitié-Salpêtrière Hospital, Paris, France
    3. Federative Institute for Neuroscience Research (IFR70), Pitié-Salpêtrière Hospital, Paris, France
    4. AP-HP, Pitié-Salpêtrière Hospital, Centre d'Investigation Clinique, Paris, France
    5. AP-HP, Pitié-Salpêtrière Hospital, Fédération des Maladies du Système Nerveux, Paris, France
    6. AP-HP, Pitié-Salpêtrière Hospital, Department of Genetics and Cytogenetics, Paris, France
    Search for more papers by this author
  • Alexis Brice MD,

    Corresponding author
    1. INSERM, U679, Paris, France
    2. Pierre and Marie Curie-Paris6 University, UMR S679, Pitié-Salpêtrière Hospital, Paris, France
    3. Federative Institute for Neuroscience Research (IFR70), Pitié-Salpêtrière Hospital, Paris, France
    4. AP-HP, Pitié-Salpêtrière Hospital, Fédération des Maladies du Système Nerveux, Paris, France
    5. AP-HP, Pitié-Salpêtrière Hospital, Department of Genetics and Cytogenetics, Paris, France
    6. Pierre and Marie Curie-Paris6 University, Pitié-Salpêtrière Medical School, Paris, France
    • INSERM U679, AP-HP, Hôpital Pitié-Salpêtrière, 47 boulevard de l'Hôpital, 75013 Paris, France

    Search for more papers by this author
  • French Parkinson's Disease Genetics study group


Abstract

Patients with parkin mutations are known to have slower PD progression and a better response to levodopa at lower doses than patients with idiopathic Parkinson's disease. To determine the effects of deep brain stimulation (DBS) on such patients, we have compared the follow-up after surgery of 7 patients with one parkin mutation, 7 patients with two parkin mutations, and 39 patients without parkin mutations. Twelve to 24 months after neurosurgery, the daily doses of levodopa equivalent were significantly lower in patients with two parkin mutations, indicating that these patients benefit from DBS, and they might have more durable results. © 2008 Movement Disorder Society

Ancillary